Nautilus Biotechnology, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Seattle, WA. Its latest filed balance sheet (2025-12-31) shows total assets of $178 million (its filed statements).
Product businessLaboratory Analytical InstrumentsSeattle, WAfilings since 20203 of 9 filed, 6 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3826, Laboratory Analytical Instruments); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.3 out of ten, 3 of 9 metrics filed and 6 estimated: past 4.5 out of ten, present 6.1 out of ten, future 5.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 2.6 out of ten. 2 warning events since 2020; the latest 2025-05-02. 26th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.5 out of ten. CrossAssetData estimate 5.5/10, confidence 20 of 100 (family median). 50th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Shareholder treatment (past): 5.5 out of ten. CrossAssetData estimate 5.5/10, confidence 35 of 100 (one part). 55th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 6.0 out of ten. ROE -38%: lost 38¢ per shareholder dollar. Leverage 18%: owes 18¢ per asset dollar. 60th percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.6 out of ten. CrossAssetData estimate 5.6/10, confidence 20 of 100 (family median). 50th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Leadership (present): 7.0 out of ten. top 30% of 21 in its family for leadership; chief executive since 2021. 70th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.8 out of ten. CrossAssetData estimate 4.8/10, confidence 35 of 100 (one part). 48th percentile among 22 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Growth drivers (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Expectations vs reality (future): 5.9 out of ten. CrossAssetData estimate 5.9/10, confidence 20 of 100 (family median). 50th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-28 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form EFFECT, 2026-09-18. Filings on record since 2020. Read from EDGAR 2026-10-12.
Who runs it
Patel, Sujal M (CEO, President, and Secretary); Mowry, Anna (CFO and Treasurer); Mallick, Parag (Chief Scientist); Suzuki, Kentaro (Chief Marketing Officer); Weld, Gwen E (Chief People Officer); Murphy, Matthew B. (General Counsel); Sankar, Subramanian (Senior VP, Product Development); Akinsanya, Karen (director); Epperly, Melissa B, (director); Mcilwain, Matthew S (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.